BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8872455)

  • 1. The synthesis and biological activities of oligodeoxynucleotides that are covalently linked to psoralen at their 5' ends.
    Wang LX; Yang DC; Lu YY; Takagi Y; Taira K; Li T; Zhang LH
    Drug Des Discov; 1995 Nov; 13(2):109-21. PubMed ID: 8872455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antisense c-Ha-ras oligodeoxynucleotides inhibit the proliferation of the gastrocarcinoma-DNA-transformed rat 3-3 cells and reduce the p21 expression of the cells.
    Xu Y; Deng GR; Liang YY; Li C
    Sci China B; 1991 Jan; 34(1):35-41. PubMed ID: 2015062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells.
    Daaka Y; Wickstrom E
    Oncogene Res; 1990; 5(4):267-75. PubMed ID: 2204019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibition of antisense DNA and its derivative on gastric transformed cell carcinogenicity].
    Yang D; Li T; Xu W
    Zhonghua Wai Ke Za Zhi; 1995 Jan; 33(1):26-8. PubMed ID: 7774440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.
    Gray GD; Hernandez OM; Hebel D; Root M; Pow-Sang JM; Wickstrom E
    Cancer Res; 1993 Feb; 53(3):577-80. PubMed ID: 8425190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras.
    Kawada M; Fukazawa H; Mizuno S; Uehara Y
    Biochem Biophys Res Commun; 1997 Feb; 231(3):735-7. PubMed ID: 9070883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Inhibitory effect of monoclonal antibody PD4 on Ha-ras transformed cells Rat3-3].
    Yin WN
    Zhonghua Zhong Liu Za Zhi; 1991 Mar; 13(2):82-6. PubMed ID: 1879298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibited neoplastic phenotype by the c-Ha-ras antisense RNA.
    Lu GR; Wu CJ; Ke Y; Xiong X; Li YJ; Liu JM; Xu Y; Xu W; Li JY; Deng GR
    Sci China B; 1991 Dec; 34(12):1485-91. PubMed ID: 1801843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutated Atf4 suppresses c-Ha-ras oncogene transcript levels and cellular transformation in NIH3T3 fibroblasts.
    Mielnicki LM; Hughes RG; Chevray PM; Pruitt SC
    Biochem Biophys Res Commun; 1996 Nov; 228(2):586-95. PubMed ID: 8920955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ha-ras and N-ras regulate MAPK activity by distinct mechanisms in vivo.
    Hamilton M; Wolfman A
    Oncogene; 1998 Mar; 16(11):1417-28. PubMed ID: 9525741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Oligonucleotides complementary to the mRNA of the c-HA-ras gene suppress human cell proliferation in culture].
    Debus N; Griaznov SM; Berdichevskiĭ FB
    Dokl Akad Nauk SSSR; 1990; 313(2):491-4. PubMed ID: 2289400
    [No Abstract]   [Full Text] [Related]  

  • 13. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.
    Delgado MD; Vaqué JP; Arozarena I; López-Ilasaca MA; Martínez C; Crespo P; León J
    Oncogene; 2000 Feb; 19(6):783-90. PubMed ID: 10698496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense properties of end-modified oligonucleotides targeted to Ha-ras oncogene.
    Saison-Behmoaras TE; Duroux I; Nguyen TT; Asseline U; Hélène C
    Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):361-8. PubMed ID: 9303188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.
    Schwab G; Chavany C; Duroux I; Goubin G; Lebeau J; Hélène C; Saison-Behmoaras T
    Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10460-4. PubMed ID: 7937975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype.
    Coppa A; Mincione G; Lazzereschi D; Ranieri A; Turco A; Lucignano B; Scarpa S; Ragano-Caracciolo M; Colletta G
    J Cell Physiol; 1997 Aug; 172(2):200-8. PubMed ID: 9258341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of apoptosis, tumorigenesity and metastatic potential with antisense H-ras oligodeoxynucleotides in a high metastatic tumor model of hepatoma: LCI-D20.
    Liao Y; Tang ZY; Ye SL; Liu KD; Sun FX; Huang Z
    Hepatogastroenterology; 2000; 47(32):365-70. PubMed ID: 10791191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (A,G)-oligonucleotides form extraordinary stable triple helices with a critical R.Y sequence of the murine c-Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells.
    Alunni-Fabbroni M; Pirulli D; Manzini G; Xodo LE
    Biochemistry; 1996 Dec; 35(50):16361-9. PubMed ID: 8973212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequence specific inhibition of in vitro translation of mutated or normal ras p21.
    Yu ZP; Chen DF; Black RJ; Blake K; Ts'o PO; Miller P; Chang EH
    J Exp Pathol; 1989; 4(2):97-108. PubMed ID: 2671311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of myeloid cell growth by distinct effectors of Ras.
    Matsuguchi T; Kraft AS
    Oncogene; 1998 Nov; 17(21):2701-9. PubMed ID: 9840934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.